Q3 2025 CytomX Therapeutics Inc Earnings Call Transcript
Key Points
- CytomX Therapeutics Inc (CTMX) has shown promising interim phase one data for its drug candidate CX 2051, demonstrating robust clinical activity in colorectal cancer (CRC) with a preliminary median progression-free survival of 5.8 months.
- The company has successfully completed a $100 million financing, positioning it well to advance CX 2051 towards later phase development.
- CX 2051 has shown potential as a pan-CRC drug, with activity observed across a broad late-stage patient population, including those with liver metastases and KRAS mutations.
- The company is expanding its pipeline with CX 801, a masked interferon alpha-2B program, showing positive initial biomarker data in advanced melanoma.
- CytomX Therapeutics Inc (CTMX) is actively exploring additional cancer indications for CX 2051, leveraging its widespread expression in various solid tumors.
- Revenue for the third quarter decreased significantly to $6 million from $33.4 million in the same period last year, primarily due to the completion of obligations in the Bristol-Myers Squibb collaboration.
- Operating expenses remain high, with R&D expenses at $15.3 million, although they have decreased compared to the previous year.
- The company faces challenges in managing gastrointestinal adverse events, particularly diarrhea, associated with CX 2051, which requires ongoing investigation and management strategies.
- Despite promising early data, the regulatory strategy for CX 2051 remains uncertain, with discussions with the FDA anticipated in 2026.
- The company is still in the early stages of development for its combination strategies, such as with bevacizumab, and has yet to determine the specific patient populations for these studies.
Good afternoon everyone.
Thank you for standing by. Welcome to the Cytomics Therapeutics 3rd quarter 2025 financial results call. Please be advised that today's call is being recorded. I would now like to have the call over to your host for today, Chris Ogden, Cytomes's Chief Financial Officer. Please go ahead.
Thank you. Good afternoon and thank you for joining us.
Before we begin, I'd like to remind everyone that during this call we'll be making forward-looking statements.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control.
Important risks and uncertainties are set forth in our most recent public filings with the FEC at SEC.gov.
We undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise.
Earlier this afternoon we issued a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
